Export 4 results:
Author Title Type [ Year(Asc)]
Filters: Author is Jala, Venkatakrishna R  [Clear All Filters]
2019
Singh R, Chandrashekharappa S, Bodduluri SR, Baby BV, Hegde B, Kotla NG, Hiwale AA, Saiyed T, Patel P, Vijay-Kumar M, Langille MGI, Douglas GM, Cheng X, Rouchka EC, Waigel SJ, Dryden GW, Alatassi H, Zhang H-G, Haribabu B, Vemula PK et al..  2019.  Enhancement of the gut barrier integrity by a microbial metabolite through the Nrf2 pathway.. Nat Commun. 10(1):89. DOI:10.1038/s41467-018-07859-7.
Totiger TM, Srinivasan S, Jala VR, Lamichhane P, Dosch AR, Gaidarski AA, Joshi C, Rangappa S, Castellanos J, Vemula PKumar, Chen X, Kwon D, Kashikar N, VanSaun M, Merchant NB, Nagathihalli NS.  2019.  Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer.. Mol Cancer Ther. 18(2):301-311. DOI:10.1158/1535-7163.MCT-18-0464.
2017
Singh R, Hegde B, Von Baby B, Sadeep C, Kotla N, Chandrasekar B, Marepally S, Bodduluri H, Vemula PK, Jala VR.  2017.  Targeted delivery of microbial metabolite, urolithin A protects from chemically (DSS or TNBS) induced colitis in pre-clinical models. The Journal of Immunology. 198:65.6–65.6.
2016
Saha P, San Yeoh B, Singh R, Chandrasekar B, Vemula PKumar, Haribabu B, Vijay-Kumar M, Jala VR.  2016.  Gut Microbiota Conversion of Dietary Ellagic Acid into Bioactive Phytoceutical Urolithin A Inhibits Heme Peroxidases.. PLoS One. 11(6):e0156811. DOI:10.1371/journal.pone.0156811.